Fly Insider: Allakos, Live Nation among week's notable insider transactions » 15:1009/2609/26/22
NLOK, ADBE, NAUT, ALLK, LYV, CRWD, AN, AMRS
Welcome to "Fly Insider,"…
|Over a week ago|
Amyris price target raised to $4 from $2.50 at Piper Sandler » 06:1709/1909/19/22
Piper Sandler analyst…
Piper Sandler analyst Korinne Wolfmeyer raised the firm's price target on Amyris to $4 from $2.50 and keeps a Neutral rating on the shares. Management noted that August posted the strongest consumer month on record for the company, and Q3 is on track to be the strongest consumer quarter yet, Wolfmeyer tells investors in a research note. The analyst is a fan of management's Fit to Win Program.
Amyris names Elizabeth Dreyer as Chief Accounting Officer » 09:0809/1409/14/22
In a regulatory 8-K…
In a regulatory 8-K filing, the company states: "On September 9, 2022, Elizabeth Dreyer agreed to join Amyris, Inc. as its Chief Accounting Officer & Corporate Controller, reporting to Han Kieftenbeld, the Company's Chief Financial Officer, effective October 11, 2022. Ms. Dreyer has over 20 years of U.S. public company accounting experience with more than 10 years of experience as Chief Accounting Officer of public companies. Most recently, she served as Chief Accounting Officer of Travel + Leisure Co., a publicly-traded global provider of hospitality services and travel products and Wyndham spin-off, from June 2018 until September 2022, after joining Wyndham Worldwide Corp. in March 2018. Previously, Ms. Dreyer served as Vice President, Controller and Chief Accounting Officer of Edgewell Personal Care Company, a manufacturer and marketer of consumer products, from January 2015 to March 2018."
Director of Akoya Biosciences Nolan sells $319K in company shares » 17:0009/1309/13/22
Director of Akoya…
Director of Akoya Biosciences Garry Nolan disclosed in a regulatory filing that he had sold 23,991 shares of company stock at $13.31 per share between September 9 and September 12, for a total transaction amount of $319,282.
Exact Sciences announces data from MCED biomaker validation study » 13:0609/1009/10/22
Exact Sciences announced…
Exact Sciences announced data from a multi-cancer early detection, or MCED, biomarker validation study was presented at the European Society for Medical Oncology Congress. The study rigorously assessed the performance of four distinct biomarker classes found in the blood and known to signal the presence of cancer regardless of its location in the body. Four biomarker classes, discovered through years of collaboration with Johns Hopkins and Mayo Clinic and analyzed together for the first time in this study, demonstrated the ability to detect cancer signal from 15 organ sites with a mean sensitivity of 61% and mean specificity of 98.2%. The multi-biomarker approach, including aneuploidy, proteins, and DNA methylation and mutations, provided encouraging cancer detection in stages I and II, with a combined sensitivity of 38.7%. The retrospective, case-control study included cancers from 11 organ sites with no recommended screening option today and 15 organ sites and tissue in total, including breast, bladder, colon, esophageal, kidney, liver, lung, multiple myeloma, myelodysplastic syndrome, non-Hodgkin's lymphoma, ovarian, pancreatic, prostate, stomach, and uterine. The non-cancer control cohort included age-matched, presumably healthy individuals and samples from individuals with non-cancer diseases to represent the intended use population more effectively. A larger case-control study is underway to further validate the results shared at ESMO and determine the final design of the MCED test. Exact Sciences will then begin recruiting patients for the FDA registrational Study Of All comeRs trial in MCED during 2023. The SOAR trial will be the largest prospective, interventional MCED trial ever conducted in the United States. Exact Sciences plans to leverage its leading presence in primary care and cancer screening to accelerate the availability of MCED and deliver this powerful innovation to patients in need.
Cathie Wood's ARK Investment bought 188K shares of Exact Sciences today 20:0509/0609/06/22
|Over a month ago|
Unusually active option classes on open August 29th » 09:4008/2908/29/22
CFVI, GSAT, CCJ, PDD, AMRS, WISH, DKNG, BMY, BBIG, UUP
Unusual total active…
Unusual total active option classes on open include: CF Acquisition Corp (CFVI), Globalstar (GSAT), Cameco (CCJ), Pinduoduo (PDD), Amyris (AMRS), ContextLogic (WISH), DraftKings (DKNG), Bristol Myers Squibb (BMY), Vinco Ventures (BBIG), and PowerShares DB US Dollar Index Bullish Fund (UUP).
Exact Sciences initiated with an Outperform at Credit Suisse » 16:3708/2408/24/22
Credit Suisse analyst Dan…
Credit Suisse analyst Dan Leonard initiated coverage of Exact Sciences with an Outperform rating and $55 price target. The company's leadership position in non-invasive colorectal cancer screening is "durable," while upcoming pipeline catalysts could "de-risk future large opportunities" like multi-cancer testing and minimal residual disease monitoring, Leonard tells investors in a research note.
Absci files $250M mixed securities shelf 16:1008/2408/24/22
Cathie Wood's ARK Investment bought 515K shares of Exact Sciences today 20:3008/2308/23/22